Litigation
Array BioPharma, Inc. v. Sandoz Inc.
settled1:22-cv-01316-GBW
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2022-10-06
- Terminated
- 2025-01-09
Patents at issue (6)
Plaintiffs (1)
Defendants (1)
Summary
Hatch-Waxman ANDA litigation brought by Array BioPharma against Sandoz over generic binimetinib. The case ended in a stipulated dismissal without prejudice under a confidential settlement and license agreement, expressly not an adjudication on the merits; Sandoz could maintain its existing Paragraph IV certifications and FDA was not barred from final ANDA approval. The dismissal order recited '9,850,299'; the narrative states the corresponding family patent is U.S. 9,850,229.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).